Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD16A | O95870 | 2/20 | 0.53 |
| ▸ | FAAH | O00519 | 13/20 | 0.49 |
| ▸ | MGLL | Q99685 | 7/20 | 0.49 |
| ▸ | LPL | P06858 | 1/20 | 0.43 |
| ▸ | LIPC | P11150 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6551212 | 0.91 | ABHD16A (0.41) | ABHD16AFAAHMGLLLPLLIPC | |
| SCHEMBL7040759 | 0.74 | ABHD16A (0.58) | ABHD16AFAAHMGLLLPLLIPC | |
| SCHEMBL2233598 | 0.73 | ABHD16A (0.72) | ABHD16AFAAHMGLLLPLLIPC | |
| SCHEMBL6599976 | 0.71 | LMNA (0.56) | ABHD16AFAAHMGLL | |
| SCHEMBL6551927 | 0.71 | KMT2A (0.52) | ABHD16AFAAHMGLLLPLLIPC | |
| SCHEMBL2233406 | 0.70 | ABHD16A (0.72) | ABHD16AFAAHMGLLLPLLIPC | |
| SCHEMBL7046228 | 0.70 | ABHD16A (0.72) | ABHD16AFAAHMGLLLPLLIPC | |
| SCHEMBL11620781 | 0.70 | FAAH (0.78) | ABHD16AFAAHMGLLLPLLIPC | |
| SCHEMBL6552647 | 0.70 | ABHD16A (0.55) | ABHD16AFAAHMGLL | |
| SCHEMBL6551881 | 0.70 | ABHD16A (0.55) | ABHD16AFAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1482929-A1 | USE OF SUBSTITUTED 3-PHENYL-5-ALKOXY-1,3,4-OXDIAZOLE-2-ONE FOR PRODUCING MEDICAMENTS THAT INHIBIT PANCREATIC LIPASE | Aventis Pharma Deutschland GmbH (DE) | 2004-12-08 | — | — | EP | disclosed |
| EP-1214302-B1 | SUBSTITUTED 3-PHENYL-5-ALKOXI-1,3,4-OXDIAZOL-2-ONES AND THEIR USE AS LIPASE INHIBITORS | AVENTIS PHARMA GMBH (DE) | 2003-10-29 | — | — | EP | disclosed |
| WO-2003072098-A1 | USE OF SUBSTITUTED 3-PHENYL-5-ALKOXY-1,3,4-OXDIAZOLE-2-ONE FOR PRODUCING MEDICAMENTS THAT INHIBIT PANCREATIC LIPASE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-04 | — | — | WO | disclosed |
| US-6596742-B1 | Inhibitory effect on the hormone-sensitive lipase, HSL. insecticides, controlling metabolism and multistage synthesis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-07-22 | — | — | US | disclosed |
| EP-1214302-A1 | SUBSTITUTED 3-PHENYL-5-ALKOXI-1,3,4-OXDIAZOL-2-ONES AND THEIR USE AS LIPASE INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001017981-A1 | SUBSTITUTED 3-PHENYL-5-ALKOXI-1,3,4-OXDIAZOL-2-ONES AND THEIR USE AS LIPASE INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-03-15 | — | — | WO | disclosed |